Journal article
Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the national cancer institute breast and prostate cancer cohort consortium
KK Tsilidis, RC Travis, PN Appleby, NE Allen, S Lindstrom, FR Schumacher, D Cox, AW Hsing, J Ma, G Severi, D Albanes, J Virtamo, H Boeing, HB Bueno-De-Mesquita, M Johansson, JR Quirós, E Riboli, A Siddiq, A Tjønneland, D Trichopoulos Show all
American Journal of Epidemiology | OXFORD UNIV PRESS INC | Published : 2012
DOI: 10.1093/aje/kwr423
Abstract
Genome-wide association studies (GWAS) have identified many single nucleotide polymorphisms (SNPs) associated with prostate cancer risk. There is limited information on the mechanistic basis of these associations, particularly about whether they interact with circulating concentrations of growth factors and sex hormones, which may be important in prostate cancer etiology. Using conditional logistic regression, the authors compared per-allele odds ratios for prostate cancer for 39 GWAS-identified SNPs across thirds (tertile groups) of circulating concentrations of insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), testosterone, androstenedione, andro..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
This study was supported by the US National Cancer Institute (grant U01-CA98233-07 to Dr. David J. Hunter, grant U01-CA98710-06 to Dr. Michael J. Thun, grant U01-CA98216-06 to Drs. Elio Riboli and Rudolf Kaaks, and grant U01-CA98758-07 to Dr. Brian E. Henderson) and by a grant from the Intramural Research Program of the US National Institutes of Health. The Melbourne Collaborative Cohort Study was supported by grants 209057, 251553, and 450104 from the Australian National Health and Medical Research Council and by infrastructure provided by Cancer Council Victoria. Dr. Konstantinos K. Tsilidis was supported by Cancer Research UK.